➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Johnson and Johnson
Moodys
Colorcon

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 6,830,923

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 6,830,923
Title: Genetics units for inhibiting the function of RNA
Abstract:The invention relates to a genetic unit, optionally present as a multiple-copy, for inhibiting RNA. The unit contains the transcription units necessary for transcription by polymerase III and a DNA coding for inhibiting RNA, which is arranged within the unit in such a way that the transcribed RNA is part of the polymerase III transcript. Using these units it is possible to achieve increased stability of the inhibiting RNA, which may occur in the form of ribozymes or antisense-RNAs, whilst maintaining an undiminished activity. The invention further relates to a process for introducing the genetic units into the cell, the use of these units and pharmaceutical preparations containing them.
Inventor(s): Beug; Hartmut (Vienna, AT), Birnstiel; Max L. (Vienna, AT), Cotten; Matthew (Vienna, AT), Wagner; Ernst (Langenzersdorf, AT), Kandolf; Harald (Vienna, AT)
Assignee: Boehringer Inglheim International GmbH (Ingelheim am Rhein, DE)
Application Number:07/947,982
Patent Claims:see list of patent claims

Details for Patent 6,830,923

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Free Forever Trial 2021-12-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Free Forever Trial 2021-12-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Harvard Business School
Colorcon
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.